Joshua Cohen (left) and Justin Klee (Amylyx)
September 2, 2020 05:07 PM EDTUpdated September 3, 07:15 AM
R&D

Amy­lyx spot­lights a PhII suc­cess in slow­ing ALS pro­gres­sion. And they’re tak­ing it to the FDA

Max Gelman

Senior Editor

Just a cou­ple months af­ter pulling in a $30 mil­lion Se­ries B round, Amy­lyx is mak­ing an­oth­er splash with what it hopes are promis­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times